NATCO Pharma Balans Gezondheid
Financiële gezondheid criteriumcontroles 6/6
NATCO Pharma heeft een totaal eigen vermogen van ₹58.5B en een totale schuld van ₹3.7B, wat de schuld-eigenvermogensverhouding op 6.3% brengt. De totale activa en totale passiva bedragen respectievelijk ₹69.1B en ₹10.5B. De EBIT NATCO Pharma is ₹19.7B waardoor de rentedekking 97.5 is. Het heeft contanten en kortetermijnbeleggingen van ₹18.5B.
Belangrijke informatie
6.3%
Verhouding schuld/eigen vermogen
₹3.71b
Schuld
| Rente dekkingsratio | 97.5x |
| Contant | ₹18.49b |
| Aandelen | ₹58.53b |
| Totaal verplichtingen | ₹10.53b |
| Totaal activa | ₹69.06b |
Recente financiële gezondheidsupdates
NATCO Pharma (NSE:NATCOPHARM) Seems To Use Debt Rather Sparingly
Jun 30
Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jan 25Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jul 16Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?
Jun 23Recent updates
We Ran A Stock Scan For Earnings Growth And NATCO Pharma (NSE:NATCOPHARM) Passed With Ease
Oct 13NATCO Pharma Limited's (NSE:NATCOPHARM) Shares Bounce 26% But Its Business Still Trails The Market
Aug 13If EPS Growth Is Important To You, NATCO Pharma (NSE:NATCOPHARM) Presents An Opportunity
Jul 15NATCO Pharma (NSE:NATCOPHARM) Seems To Use Debt Rather Sparingly
Jun 30NATCO Pharma Limited's (NSE:NATCOPHARM) Earnings Are Not Doing Enough For Some Investors
Jun 14NATCO Pharma Limited (NSE:NATCOPHARM) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models
May 30Calculating The Fair Value Of NATCO Pharma Limited (NSE:NATCOPHARM)
May 09Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?
Apr 03NATCO Pharma (NSE:NATCOPHARM) Is Due To Pay A Dividend Of ₹1.25
Feb 21NATCO Pharma Limited Just Beat EPS By 223%: Here's What Analysts Think Will Happen Next
Feb 18NATCO Pharma Limited (NSE:NATCOPHARM) Surges 25% Yet Its Low P/E Is No Reason For Excitement
Feb 17Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jan 25An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 37% Undervalued
Jan 09Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?
Dec 13An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 42% Undervalued
Sep 30Here's Why We Think NATCO Pharma (NSE:NATCOPHARM) Might Deserve Your Attention Today
Sep 12NATCO Pharma (NSE:NATCOPHARM) Is Paying Out A Larger Dividend Than Last Year
Aug 12Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jul 16NATCO Pharma Limited (NSE:NATCOPHARM) Shares Could Be 44% Below Their Intrinsic Value Estimate
Apr 20Is NATCO Pharma Limited (NSE:NATCOPHARM) Trading At A 46% Discount?
Dec 20NATCO Pharma's (NSE:NATCOPHARM) Upcoming Dividend Will Be Larger Than Last Year's
Aug 12Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?
Jun 23Broker Revenue Forecasts For NATCO Pharma Limited (NSE:NATCOPHARM) Are Surging Higher
Jun 02Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( ₹40.2B ) NATCOPHARM } overtreffen de korte termijn passiva ( ₹9.7B ).
Langlopende schulden: De kortetermijnactiva NATCOPHARM ( ₹40.2B ) overtreffen de langetermijnschulden ( ₹804.0M ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: NATCOPHARM heeft meer geld in kas dan de totale schuld.
Schuld verminderen: De schuld/eigen vermogen-ratio van NATCOPHARM is de afgelopen 5 jaar gedaald van 11.1% naar 6.3%.
Schuldendekking: De schuld van NATCOPHARM wordt goed gedekt door de operationele kasstroom ( 326.4% ).
Rentedekking: De rentebetalingen op de schuld van NATCOPHARM worden goed gedekt door EBIT ( 97.5 x dekking).